… Upf1 has recently been shown to interact with eukaryotic release factor (eRF)1 (F
Lejeune and LE Maquat, unpublished) and eRF3 (G Singh and J Lykke-Andersen, personal …

… The tumours underwent massive haemorrhagic necrosis, hence the name tumour necrosis
factor. The same authors found evidence that the tumour-associated vessels were the prime …

… extramural re-evaluation of the results using very strict criteria (F LeJeune, unpublished data)
downgraded the rate of complete response rate to 78% and increased the partial response …

From September, 1967, to January, 1974, a clinical trial was carried out by the WHO
Melanoma Group to evaluate the efficacy of elective lymph-node dissection in the treatment of …

PURPOSE To determine the toxicity and the therapeutic efficacy of the combination of the
recombinant tumor necrosis factor alpha (rTNF alpha), recombinant interferon gamma (rIFN-…

Results of a prospective randomized clinical trial conducted by the WHO Collaborating Centers
for the Evaluation of Methods of Diagnosis and Treatment of Melanoma are reported. Five…

The induction of potent CD8+ T cell responses by vaccines to fight microbes or tumors
remains a major challenge, as many candidates for human vaccines have proved to be poorly …

Agomelatine (S20098) displayed pK i values of 6.4 and 6.2 at native (porcine) and cloned,
human (h)5-hydroxytryptamine (5-HT) 2C receptors, respectively. It also interacted with h5-HT …

Although wide surgical excision is the accepted treatment for thin malignant melanomas,
there is reason to believe that narrower margins may be adequate. We conducted a …

Using fluorescent HLA-A*0201 tetramers containing the immunodominant Melan-A/MART-1
(Melan-A) tumor-associated antigen (Ag), we previously observed that metastatic lymph …